Board & Management
Cancure’s Directors are supported by current investors, independent advisors, and Executive Managers under contract with Bio-Link Australia Pty Ltd.
Dr Ian Nisbet, PhD
Ian has over 30 years of drug development, business development and general management experience in the local and international biotechnology sector. He is a co-founder and partner in the biotechnology consulting company Afandin Pty Ltd and a co-founder and Executive Director of the oncology drug development company Senz Oncology Pty Ltd. He has previously been CEO/MD of Xenome Ltd and Meditech Research Ltd and held senior management positions at Millennium Pharmaceuticals Inc, ChemGenex Pharmaceuticals Ltd and CSL Ltd. Ian has a part-time appointment as Deputy Director (Commercialisation) at the Australian Institute for Bioengineering and Nanotechnology (AIBN) at the University of Queensland. He currently serves as Chairman of vivoPharm Pty Ltd and is a non-Executive Director of Solagran Ltd, ACYTE Biotech Pty Ltd, Cerulean Pharma Australia Pty Ltd, Tunitas Therapeutics Australia Pty Ltd and MyoKardia Australia Pty Ltd.
Ian has led teams that have developed (so far) two FDA-approved drugs; restructured, repositioned and revitalised two companies as CEO; co-founded two companies; negotiated multiple in- or out-licensing transactions; and played a leadership role in several M&A transactions involving biotechnology companies.
Selected highlights at different companies include:
• Millennium Pharmaceuticals, Inc. (Cambridge, MA) (1998 – 2004)
• ChemGenex Pharmaceuticals Ltd. (2006 – 2008)
• Meditech Research Ltd. (2004 – 2006)
• Xenome Ltd. (2008 – 2010)
• vivoPharm Pty. Ltd. (2011 – )
Mr Christopher Boyer, BS MBA
Mr Boyer specialises in the selling of biotechnology, the culmination of his 20+ year career spanning its discovery, development and commercialisation. Most recently, as Executive Director of Bio-Link, Mr Boyer led licensing efforts for a range of drug and diagnostic opportunities and brought several deals to fruition.
Prior to joining Bio-Link, Mr Boyer served as Business Development Manager at Cryptome Pharmaceuticals, a Melbourne-based peptide therapeutics developer. Earlier he was Manager, Corporate and Strategic Development at San Diego-based drug developer NewBiotics, where he negotiated contracts and contributed to a major co-development deal in cancer chemotherapeutics.
Mr Boyer also consulted to San Diego’s Halozyme Therapeutics, a developer of therapeutic enzymes, preparing project valuations in support of a successful capital raising. Mr Boyer draws upon deep technical insights acquired during his extensive R&D experience in small molecule drug discovery and molecular neuroscience, attained at Novartis and the Howard Hughes Medical Institute respectively. He earned a BS in Animal Physiology and Neuroscience from the University of California, San Diego, and augmented his business skills with an MBA in Marketing from the University of San Diego.
Dr Andrew M Coley, PhD
Dr Coley’s expertise is in early-stage biotechnology development. He was appointed Chief Scientific Officer of TransBio Limited in 2007, a position he held for seven years. His roles have included oversight of the Cancer and Autoimmunity Biomarker Research Portfolio, project management, intellectual property management and licensing.
Dr Coley qualified in diagnostic pathology in the UK. He completed his pathology rotation at Bedford General Hospital and Addenbrookes, Cambridge, specialising in medical microbiology and immunology. After earning his PhD in immunology and cell biology at the Royal Postgraduate Medical School and University College London, he undertook postdoctoral research into the human immune response to the malaria parasite, Plasmodium falciparum, at La Trobe University, Melbourne.
Dr Coley was later appointed Senior Lecturer/Senior Research Fellow at La Trobe University’s School of Molecular Science, and Education Director of the CRC for Biomarker Translation. He is a member of the Editorial Board of Cell Biology Insights, and of the NHMRC Translational Research Faculty.
Mr Sydney Evans, B.Com, LLB
Mr Sydney Evans is a commercial lawyer with degrees in Commerce and Law from the University of New South Wales, and a Bachelor of Arts with First-Class Honours from the University of Sydney.
Mr Evans gained valuable intellectual property law experience as a lawyer for Mallesons Stephen Jaques (now King & Wood Mallesons). He also worked in mergers and acquisitions with the merchant banking department of Pittsburgh National Bank’s Australian division.
Now semi-retired, Mr Evans devotes significant time to providing Cancure with legal and accounting expertise.
Mr Craig Miles
Mr Craig Miles has over 19 years’ project management experience, specialising in funds management, property development and construction.
Mr Miles gained sales, leasing, development and project management experience at Mirvac, with major projects including Quay Grand, the Renzo Piano Apartments, and the Olympic Village. Craig further enhanced his industry knowledge at MTM Funds Management, overseeing Entertainment Trust Properties’ asset management, development delivery and property management.
After several residential developments, Mr Miles founded The Property Lab (TPL) with John Wills, focusing on sustainable projects. TPL launched a sustainable property fund with Orchard Funds Management in 2006, which grew to $120m in assets.
Associate Professor Stephen Ralph
Dr Stephen Ralph is Associate Professor at Griffith University, heading Vaccine Development at the Gold Coast Campus. Internationally recognised in cancer immunology and vaccines, Dr Ralph has devoted over two decades to research and development.
Dr Ralph has authored extensive peer-reviewed publications, and has frequently been awarded grant funding by the National Health and Medical Research Council and Cancer Council Australia. He holds a BSc in Biochemistry and Physiology from the University of Otago, New Zealand; an MSc in Cell Biology (Honours) from the University of Auckland, New Zealand; and an MBA from the Royal Melbourne Institute of Technology.
As Cancure’s Chief Scientist, Dr Ralph brings a valuable network of oncologists and cancer researchers to advance Cancure’s drug development programs and candidates for the benefit of cancer patients.